A Physiologically Based Pharmacokinetic Model to Optimize the Dosage Regimen and Withdrawal Time of Cefquinome in Pigs

Overview

Journal PLoS Comput Biol

Specialty Biology

Date 2023 Aug 16

PMID 37585381

Authors

Kun Mi

Lei Sun

Yixuan Hou

Xin Cai

Kaixiang Zhou

Wenjin Ma

Xiangyue Xu

Yuanhu Pan

Zhenli Liu

Lingli Huang

Affiliations

Soon will be listed here.

Abstract

Cefquinome is widely used to treat respiratory tract diseases of swine. While extra-label dosages of cefquinome could improve clinical efficacy, they might lead to excessively high residues in animal-derived food. In this study, a physiologically based pharmacokinetic (PBPK) model was calibrated based on the published data and a microdialysis experiment to assess the dosage efficiency and food safety. For the microdialysis experiment, in vitro/in vivo relative recovery and concentration-time curves of cefquinome in the lung interstitium were investigated. This PBPK model is available to predict the drug concentrations in the muscle, kidney, liver, plasma, and lung interstitial fluid. Concentration-time curves of 1000 virtual animals in different tissues were simulated by applying sensitivity and Monte Carlo analyses. By integrating pharmacokinetic/pharmacodynamic target parameters, cefquinome delivered at 3-5 mg/kg twice daily is advised for the effective control of respiratory tract infections of nursery pig, which the bodyweight is around 25 kg. Based on the predicted cefquinome concentrations in edible tissues, the withdrawal interval is 2 and 3 days for label and the extra-label doses, respectively. This study provides a useful tool to optimize the dosage regimen of cefquinome against respiratory tract infections and predicts the concentration of cefquinome residues in edible tissues. This information would be helpful to improve the food safety and guide rational drug usage.

Citing Articles

A physiologically based pharmacokinetic/pharmacodynamic model to determine dosage regimens and withdrawal intervals of aditoprim against .

Mi K, Sun L, Zhang L, Tang A, Tian X, Hou Y Front Pharmacol. 2024; 15:1378034.

PMID: 38694922 PMC: 11061430. DOI: 10.3389/fphar.2024.1378034.

References

Mi K, Li M, Sun L, Hou Y, Zhou K, Hao H . Determination of Susceptibility Breakpoint for Cefquinome against in Pigs. Antibiotics (Basel). 2021; 10(8). PMC: 8389024. DOI: 10.3390/antibiotics10080958. View

Lin Z, Li M, Gehring R, Riviere J . Development and application of a multiroute physiologically based pharmacokinetic model for oxytetracycline in dogs and humans. J Pharm Sci. 2014; 104(1):233-43. DOI: 10.1002/jps.24244. View

Nahar N, Turni C, Tram G, Blackall P, Atack J . Actinobacillus pleuropneumoniae: The molecular determinants of virulence and pathogenesis. Adv Microb Physiol. 2021; 78:179-216. DOI: 10.1016/bs.ampbs.2020.12.001. View

Li X, Wu W, Su D, Wang Z, Jiang H, Shen J . Pharmacokinetics and bioavailability of cefquinome in healthy piglets. J Vet Pharmacol Ther. 2008; 31(6):523-7. DOI: 10.1111/j.1365-2885.2008.00989.x. View

Cohen Hubal E, Wetmore B, Wambaugh J, El-Masri H, Sobus J, Bahadori T . Advancing internal exposure and physiologically-based toxicokinetic modeling for 21st-century risk assessments. J Expo Sci Environ Epidemiol. 2018; 29(1):11-20. PMC: 6760598. DOI: 10.1038/s41370-018-0046-9. View

Yang B, Gao J, Cao X, Wang Q, Sun G, Yang J . Lung microdialysis study of florfenicol in pigs after single intramuscular administration. J Vet Pharmacol Ther. 2017; 40(5):530-538. DOI: 10.1111/jvp.12387. View

Mi K, Sun D, Li M, Hao H, Zhou K, Liu Z . Evidence for Establishing the Clinical Breakpoint of Cefquinome against Haemophilus Parasuis in China. Pathogens. 2021; 10(2). PMC: 7912692. DOI: 10.3390/pathogens10020105. View

Zhang P, Zhang C, Aragon V, Zhou X, Zou M, Wu C . Investigation of Haemophilus parasuis from healthy pigs in China. Vet Microbiol. 2019; 231:40-44. DOI: 10.1016/j.vetmic.2019.02.034. View

Li M, Gehring R, Riviere J, Lin Z . Probabilistic Physiologically Based Pharmacokinetic Model for Penicillin G in Milk From Dairy Cows Following Intramammary or Intramuscular Administrations. Toxicol Sci. 2018; 164(1):85-100. DOI: 10.1093/toxsci/kfy067. View

10.

Chou W, Lin Z . Development of a Gestational and Lactational Physiologically Based Pharmacokinetic (PBPK) Model for Perfluorooctane Sulfonate (PFOS) in Rats and Humans and Its Implications in the Derivation of Health-Based Toxicity Values. Environ Health Perspect. 2021; 129(3):37004. PMC: 7969127. DOI: 10.1289/EHP7671. View

11.

Rottboll L, Skovgaard K, Barington K, Jensen H, Friis C . Intrabronchial Microdialysis: Effects of Probe Localization on Tissue Trauma and Drug Penetration into the Pulmonary Epithelial Lining Fluid. Basic Clin Pharmacol Toxicol. 2015; 117(4):242-50. DOI: 10.1111/bcpt.12403. View

12.

Liverani M, Waage J, Barnett T, Pfeiffer D, Rushton J, Rudge J . Understanding and managing zoonotic risk in the new livestock industries. Environ Health Perspect. 2013; 121(8):873-7. PMC: 3734490. DOI: 10.1289/ehp.1206001. View

13.

Lin Z, Monteiro-Riviere N, Kannan R, Riviere J . A computational framework for interspecies pharmacokinetics, exposure and toxicity assessment of gold nanoparticles. Nanomedicine (Lond). 2015; 11(2):107-19. DOI: 10.2217/nnm.15.177. View

14.

Li M, Cheng Y, Chittenden J, Baynes R, Tell L, Davis J . Integration of Food Animal Residue Avoidance Databank (FARAD) empirical methods for drug withdrawal interval determination with a mechanistic population-based interactive physiologically based pharmacokinetic (iPBPK) modeling platform: example for.... Arch Toxicol. 2019; 93(7):1865-1880. DOI: 10.1007/s00204-019-02464-z. View

15.

Zhou K, Huo M, Ma W, Mi K, Xu X, Algharib S . Application of a Physiologically Based Pharmacokinetic Model to Develop a Veterinary Amorphous Enrofloxacin Solid Dispersion. Pharmaceutics. 2021; 13(5). PMC: 8143505. DOI: 10.3390/pharmaceutics13050602. View

16.

Yang F, Lin Z, Riviere J, Baynes R . Development and application of a population physiologically based pharmacokinetic model for florfenicol and its metabolite florfenicol amine in cattle. Food Chem Toxicol. 2019; 126:285-294. DOI: 10.1016/j.fct.2019.02.029. View

17.

Zhou K, Liu A, Ma W, Sun L, Mi K, Xu X . Apply a Physiologically Based Pharmacokinetic Model to Promote the Development of Enrofloxacin Granules: Predict Withdrawal Interval and Toxicity Dose. Antibiotics (Basel). 2021; 10(8). PMC: 8388861. DOI: 10.3390/antibiotics10080955. View

18.

Cristinacce A, Wright J, MacPherson M, Iaconis J, Das S . Comparing probability of target attainment against Staphylococcus aureus for ceftaroline fosamil, vancomycin, daptomycin, linezolid, and ceftriaxone in complicated skin and soft tissue infection using pharmacokinetic/pharmacodynamic models. Diagn Microbiol Infect Dis. 2020; 99(4):115292. DOI: 10.1016/j.diagmicrobio.2020.115292. View

19.

Toutain P, Bousquet-Melou A, Damborg P, Ferran A, Mevius D, Pelligand L . En Route towards European Clinical Breakpoints for Veterinary Antimicrobial Susceptibility Testing: A Position Paper Explaining the VetCAST Approach. Front Microbiol. 2018; 8:2344. PMC: 5736858. DOI: 10.3389/fmicb.2017.02344. View

20.

Viel A, Henri J, Bouchene S, Laroche J, Rolland J, Manceau J . A Population WB-PBPK Model of Colistin and its Prodrug CMS in Pigs: Focus on the Renal Distribution and Excretion. Pharm Res. 2018; 35(5):92. DOI: 10.1007/s11095-018-2379-4. View